Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SPTX

Seaport Therapeutics Inc

20.34

Aug 03 • 11:51 AM ET -0.12 (-0.61%)

Healthcare Biotechnology USA Small NASD

Today, 10:15 AMSeaport Therapeutics reports Q2 2026 EPS -$1.78 on zero revenue, misses EPS but beats revenue estimates

Peers: AVLN ABCL ABSI ABEO AAPG ACAD ABVX ARWR ABOS ARQT

| Held by: VTI VXF SCHA SBIO SCHB VTWO WCEO VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	1.09B
Enterprise Value	1.24B
Income	-
Sales	-
Book/sh	-2.16
Cash/sh	3.41
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	54
IPO	May 01, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	5.96
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.24
Current Ratio	13.24
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.45
EPS next Q	-0.57
EPS this Y	81.64%
EPS next Y	57.70%
EPS next 5Y	56.84%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 03 BMO
EPS/Sales Surpr.	-186.91% -

Insider Own	67.29%
Insider Trans	3.19%
Inst Own	5.96%
Inst Trans	22.45%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.83%
SMA50	5.50%
SMA200	9.11%
Trades

Shs Outstand	53.53M
Shs Float	17.51M
Short Float	11.31%
Short Ratio	6.42
Short Interest	1.98M
52W High	23.00 -11.58%
52W Low	14.85 36.94%
Volatility	6.79% 8.97%
ATR (14)	1.51
RSI (14)	50.62
Beta	-
Rel Volume	0.20
Avg Volume	308.53K
Volume	24,702

Perf Week	-1.00%
Perf Month	-1.14%
Perf Quarter	2.50%
Perf Half Y	-
Perf YTD	-3.16%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.33
Target Price	38.00
Prev Close	20.46
Price	20.34
Change	-0.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-15-26	Initiated	H.C. Wainwright	Buy	$50
May-26-26	Initiated	Stifel	Buy	$30
May-26-26	Initiated	Leerink Partners	Outperform	$35
May-26-26	Initiated	JP Morgan	Overweight	$42
May-26-26	Initiated	Citigroup	Buy	$35

Today 07:00AM	Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (Business Wire)
Jun-09-26 02:00AM	PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire) +9.01%
Jun-08-26 07:00AM	Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire)
Jun-01-26 07:00AM	Seaport Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire) -5.83%

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company was founded on April 1, 2024 and is headquartered in Boston, MA.

Founder & Non-Employee Chair of the BoardDr. Steven M. Paul M.D.

FounderMs. Daphne Zohar

Co-Founder & Chief Scientific OfficerDr. Michael Cunyuan Chen Ph.D.

Chief Medical Officer & President of Clinical DevelopmentDr. Antony Loebel M.D.

Chief Financial OfficerMs. Lauren A. White M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HOMBACH ROBERT J.	Director	Jun 22 '26	Buy	18.14	13,000	235,768	13,000	Jun 24 06:05 AM
ARCH Venture Partners XII, LLC	10% Owner	May 04 '26	Buy	18.00	1,100,000	19,800,000	6,294,951	May 04 06:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPTX

Seaport Therapeutics Inc

Upgrade your Finviz experience